Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Zhuhai Beihai Biotech Co. Ltd. is prosecuting 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 3 distinct examiners. The profile indicates that 2 distinct art units are involved in reviewing these matters. This variety in examiners and art units suggests that the company's biotechnology applications are being assessed from multiple technical perspectives within the patent office.
WELLS, LAUREN QUINLAN is the busiest examiner for the company, holding 1 busiest examiner pending action. With 3 pending office actions and 3 distinct examiners, the workload is spread evenly across the assigned personnel. Each examiner is responsible for 1 of the 3 pending actions, which prevents any single examiner from having a disproportionate impact on the company's current patent portfolio.
Practitioners should monitor the 2 distinct art units for any differences in how they apply biotechnology-specific examination guidelines. Coordinating responses across the 3 distinct examiners may also help maintain consistency in the company's technical arguments.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| WELLS, LAUREN QUINLAN | 1 | 48.4% | +60.3% |
| CRAIG, KAILA ANGELIQUE | 1 | 33.8% | +25.2% |
| ATKINSON, JOSHUA ALEXANDER | 1 | 52.4% | +26.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18044309 | FORMULATIONS OF CABAZITAXEL | CRAIG, KAILA ANGELIQUE | 41d |
| 17789622 | FORMULATIONS OF DOCETAXEL | ATKINSON, JOSHUA ALEXANDER | 70d |
| 18839035 | DOCETAXEL COMPOSITIONS AND METHODS | WELLS, LAUREN QUINLAN | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18839035 | DOCETAXEL COMPOSITIONS AND METHODS | WELLS, LAUREN QUINLAN | — | §102§103DP | Non-Final OA | — | Pending | Aug 16, 2024 |
| 18044309 | FORMULATIONS OF CABAZITAXEL | CRAIG, KAILA ANGELIQUE | 1618 | §103 | Final Rejection | 41d | Pending | Mar 07, 2023 |
| 17789622 | FORMULATIONS OF DOCETAXEL | ATKINSON, JOSHUA ALEXANDER | 1612 | §103DPOther | Non-Final OA | 70d | Pending | Jun 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial